Atlas Genetics raises $20M; Apple watch to debut in April;

@FierceMedDev: ICYMI yesterday: Abiomed shares hit all-time high due to strong demand for its Impella heart pumps. Article | Follow @FierceMedDev

@EmilyWFierce: Gilead zooms past AbbVie in hep C race with UnitedHealth deal. More | Follow @EmilyWFierce

> Atlas Genetics has raised $20 million in a Series C round to develop its ultrarapid point-of-care diagnostic tests for infectious diseases. Its io(R) system is expected to launch in Europe later this year with a first test for chlamydia. Investors include RMI Partners, Novartis Venture Funds, Consort Medical, Johnson & Johnson Innovation, LSP, BB Biotech Ventures and South West Ventures Fund. Release

> A survey of medical device executives by an industry group reveals that they expect to plow money from a long-hoped-for repeal of the medical device excise tax back into hiring employees. No tax, more job growth. Story

> The highly anticipated Apple watch, which is expected to track various types of health data including heart rate, is expected to debut in April. Some medical device companies, including continuous glucose monitor maker Dexcom ($DXCM), are already anticipating integrating with it. Story

> Samsung's latest Galaxy phone is rumored to be getting a case that includes a glucose monitor. Story

Biotech News

@FierceBiotech: AstraZeneca bolts together a top transatlantic team for CRISPR R&D. Report | Follow @FierceBiotech

@JohnCFierce: If you contrast the $NVS approach to CRISPR and $AZN's, $NVS seems much more focused. | Follow @JohnCFierce

@DamianFierce: Christoph Westphal's Flex Pharma prices an $86.4M IPO. News | Follow @DamianFierce

> One big reason why CNS drug development has foundered. More

> Merck KGaA abandons Symphogen's cancer drug ahead of Phase III. Article

> AnaMar rethinks pipeline after analyzing ashes of failed trial. Story

> Karolinska Development CEO leaves 3 months after taking the job. Report

Pharma News

@FiercePharma: GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. More from FierceVaccines | Follow @FiercePharma

@EricPFierce: Do you want to know about the newest stents or heart valves approved by the FDA in 2014. Read on. Feature | Follow @EricPFierce

> Ex-FDA chief testifies against J&J in Risperdal liability case. More

> Looking to get out of the hot seat, Salix to restate financials for past 7 quarters. Story

> Gilead zooms past AbbVie in hep C race with UnitedHealth deal. Report

> Trans-Pacific trade talks on biologics not even close to agreement: USTR. Article

Vaccines News

> Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything. Article

> Pfizer's Prevenar price cut 'inadequate,' critics say. More

> Serum threatens Merck's Gardasil with low-cost competitor. Story

> First batch of GSK/NIH Ebola candidate shipped for Phase III trial in Liberia. Report

> GSK to divest meningitis shots in exchange for EU clearance of Novartis deal. Item

Pharma Manufacturing News

> Chinese Pharmacopoeia venture up and running as safety push continues. More

> AmerisourceBergen again reports big leaps in revenue and earnings. Report

> GSK awards contract for API plant in Scotland. News

> International regulators offer to help India build expertise. Story

> Ranbaxy earnings pulled back down by manufacturing issues. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.